Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Biofrontera (BFRI) over the last 4 years, with Sep 2025 value amounting to $15.4 million.

  • Biofrontera's Liabilities and Shareholders Equity fell 16.75% to $15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year decrease of 19.82%. This contributed to the annual value of $22.1 million for FY2024, which is 20.88% down from last year.
  • Latest data reveals that Biofrontera reported Liabilities and Shareholders Equity of $15.4 million as of Q3 2025, which was down 23.47% from $20.1 million recorded in Q2 2025.
  • Biofrontera's Liabilities and Shareholders Equity's 5-year high stood at $55.1 million during Q3 2022, with a 5-year trough of $15.4 million in Q3 2021.
  • For the 3-year period, Biofrontera's Liabilities and Shareholders Equity averaged around $24.3 million, with its median value being $21.8 million (2024).
  • Per our database at Business Quant, Biofrontera's Liabilities and Shareholders Equity surged by 258.60% in 2022 and then plummeted by 45.71% in 2024.
  • Quarterly analysis of 5 years shows Biofrontera's Liabilities and Shareholders Equity stood at $53.2 million in 2021, then declined by 4.39% to $50.9 million in 2022, then slumped by 45.11% to $27.9 million in 2023, then fell by 20.88% to $22.1 million in 2024, then decreased by 16.75% to $15.4 million in 2025.
  • Its Liabilities and Shareholders Equity was $15.4 million in Q3 2025, compared to $20.1 million in Q2 2025 and $16.6 million in Q1 2025.